SIM
VNDA icon

SummerHaven Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

SummerHaven Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-52,256
Closed -$344K – 266
2023
Q2 		$344K Sell
52,256
-19,191
-27% -$123K 0.22% 185
2023
Q1 		$485K Buy
71,447
+2,391
+3% +$16.8K 0.28% 186
2022
Q4 		$510K Buy
69,056
+1,054
+2% +$10.3K 0.3% 189
2022
Q3 		$672K Buy
+68,002
New +$718K 0.47% 126

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SummerHaven Investment Management's VNDA Position: Q3 2023 in Review

SummerHaven Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 52,256 shares — an estimated $344K sold.

SummerHaven Investment Management first reported a position in VNDA in Q3 2022 and held it in 4 quarters. The position peaked at $672K in Q3 2022. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

  • SummerHaven Investment Management reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • SummerHaven Investment Management sold 52,256 Vanda Pharmaceuticals shares in Q3 2023, an estimated $344K.
  • SummerHaven Investment Management first reported a position in Vanda Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • SummerHaven Investment Management's Vanda Pharmaceuticals position peaked at $672K in Q3 2022.
  • 179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on SummerHaven Investment Management's 13F filing for Q3 2023, filed 13 Oct 2023.